ArticleACS applied materials & interfaces2024
Optimization of Reactive Ink Formulation for Controlled Additive Manufacturing of Copolymer Membrane Functionalization.
Article in ACS applied materials & interfaces, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rules of life at the interface of calcium signaling and mechanobiology.APL bioengineering · 2025Review
- Characterizing Transport Properties of Surface Charged Nanofiltration Membranes via Model-Based Data Analytics.Industrial & engineering chemistry research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifunctional, nanostructured membranes hold immense promise for overcoming permeability-selectivity trade-offs and enhancing membrane durability in challenging molecule separations. Following the fabrication of copolymer membranes, additive manufacturing technologies can introduce reactive inks onto substrates to modify pore wall chemistries. However, large-scale implementation is hindered by a lack of systematic optimization. This study addresses this challenge by elucidating the membrane functionalization mechanisms and optimal manufacturing conditions using a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) "click" reaction. Leveraging a data science toolkit (e.g., nonlinear regression, uncertainty quantification, identifiability analyses, model selection, and design of experiments), we developed two mathematical models: (1) algebraic equations to predict equilibrium concentrations after preparing reactive inks by mixing copper sulfate, ascorbic acid (AA), and an alkynyl-terminated reactant; and (2) reaction-diffusion partial differential equations (PDEs) to describe the functionalization process. The ink preparation chemistry with side reactions was validated through pH and UV-vis measurements, while the diffusion and kinetic parameters in the PDE model were calibrated using time-series conversion of the azide moieties inferred from Fourier-transform infrared spectroscopy. This modeling framework avoids redundant experimental efforts and offers a functionalization protocol for scaling up designs. Ink optimization problems were proposed to reduce the use of expensive and environmentally insulting ink materials, i.e., Cu(II), while ensuring the desired chemical distributions. With optimal ink formulation Cu(II)/AA/alkyne = 1:1:2 identified, we uncovered trade-offs between Cu(II) usage and functionalization time; for example, in continuous roll-to-roll manufacturing with a conserved functionalization bath setup, our optimal operational conditions to achieve ≥90% functionalization enable at least a 20% reduction in total copper investment compared to previous experimental results. The data science-enabled ink optimization framework is extendable for on-demand multifunctional membranes in numerous future applications such as metal recovery from wastewater and brine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.